Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael S Rafii

Showing results (1-10 of 129) with videos related to

Pageof 13
Sort By:
Reviews on Recent Clinical Trials|March 9, 2010
The pulse of drug development for Alzheimer's diseaseMichael S Rafii
The Journal of Prevention of Alzheimer'S Disease|May 8, 2026
Beyond amyloid positivity: Biological heterogeneity in the real-world use of lecanemabMichael S Rafii
CNS Drugs|June 9, 2016
Improving Memory and Cognition in Individuals with Down SyndromeMichael S Rafii
Journal of Alzheimer'S Disease : JAD|August 1, 2014
Preclinical Alzheimer's disease therapeuticsMichael S Rafii
Lancet (London, England)|November 20, 2016
Targeting tau protein in Alzheimer's diseaseMichael S Rafii
The Journal of Prevention of Alzheimer'S Disease|July 24, 2025
Targeting tau for Alzheimers disease through OGA inhibitionMichael S Rafii
CNS Drugs|June 8, 2020
Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention TrialsMichael S Rafii
The Lancet. Neurology|December 23, 2021
Development of treatments for Down syndromeMichael S Rafii
The Lancet. Neurology|September 3, 2018
Diagnostic biomarkers of Alzheimer's disease in Down syndromeMichael S Rafii
Developmental Neurobiology|December 12, 2018
Tau PET Imaging for Staging of Alzheimer's Disease in Down SyndromeMichael S Rafii
Pageof 13

Showing results (1-10 of 129) with videos related to

Sort By:
Pageof 13
Reviews on Recent Clinical Trials|March 9, 2010
The pulse of drug development for Alzheimer's diseaseMichael S Rafii
The Journal of Prevention of Alzheimer'S Disease|May 8, 2026
Beyond amyloid positivity: Biological heterogeneity in the real-world use of lecanemabMichael S Rafii
CNS Drugs|June 9, 2016
Improving Memory and Cognition in Individuals with Down SyndromeMichael S Rafii
Journal of Alzheimer'S Disease : JAD|August 1, 2014
Preclinical Alzheimer's disease therapeuticsMichael S Rafii
Lancet (London, England)|November 20, 2016
Targeting tau protein in Alzheimer's diseaseMichael S Rafii
The Journal of Prevention of Alzheimer'S Disease|July 24, 2025
Targeting tau for Alzheimers disease through OGA inhibitionMichael S Rafii
CNS Drugs|June 8, 2020
Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention TrialsMichael S Rafii
The Lancet. Neurology|December 23, 2021
Development of treatments for Down syndromeMichael S Rafii
The Lancet. Neurology|September 3, 2018
Diagnostic biomarkers of Alzheimer's disease in Down syndromeMichael S Rafii
Developmental Neurobiology|December 12, 2018
Tau PET Imaging for Staging of Alzheimer's Disease in Down SyndromeMichael S Rafii
Pageof 13